Chlorhexidine and newborn omphalitis and mortality

Authors' reply
Stephen Hodgins says that cord application of chlorhexidine protects infants against omphalitis equally after birth at home or in hospital, and that we were incorrect to say that it was not eff ective for infants born in hospital. The first point is well taken. The 2015 Cochrane review 1 suggests that risk ratios (RR) for omphalitis were similar in hospital (RR 0·48, 95% CI 0·28-0·84) and community trials (0·48, 0·40-0·57). The 2013 Cochrane review 2 included nine relevant hospital studies of chlorhexidine application. For omphalitis, one study 3 suggested a benefi t versus dry cord care (0·28, 0·06-1·35); another study 4 found no benefit versus alcohol (2·77, 0·12-66·49), and another 5 found no benefi t over hydrophobic gauze (1·36, 0·55-3·36). Imdad and colleagues 2 suggested that, "…compared with dry cord care, no antiseptic was convincingly advantageous to reduce the incidence of omphalitis."
The 2015 Cochrane review addressed cord cleansing, more extensive skin cleansing, and maternal vaginal washing.
1 One trial 6 in India suggested that, compared with dry cord care, chlorhexidine cord cleansing was associated with a non-significant reduction in mortality (RR 0·11, 95% CI 0·01-2·04). This and a trial in Germany 3 suggested that chlorhexidine cord cleansing was associated with lower risk of omphalitis. The review 1 made no recommendation for hospital births, saying that the "…quality of evidence for the eff ects on infection are moderate for cord application".
The trial in Germany 3 compared healthy term infants (>2500 g) in two neonatal nurseries treated with chlorhexidine 1% powder (337 infants) or dry cord care (332 infants). Sample size was based on the primary outcome of cord separation time but recruitment shortfalls necessitated respecification of the detectable difference. Hodgins summarises adverse events. Omphalitis was identified in two infants in the chlorhexidine group and seven in the dry cord care group. All cases but one were described as mild. The 2015 Cochrane review 1 downgraded its classifi cation because of "…serious risk of selection bias, performance bias and detection bias".
The trial in India 6 compared application of chlorhexidine 2·5% solution to the cords of 70 infants with dry cord care for 70 infants, all of them older than 32 weeks and weighing more than 1499 g and judged on enrolment as likely to spend at least 5 days in a neonatal intensive care unit. The sample size was again based on the primary outcome of cord separation time. Culture-confirmed sepsis was lower in the chlorhexidine group (RR 0·13, 95% CI 0·02-0·40). The 2015 Cochrane review 1 downgraded its classifi cation of bias risk because of imprecision. Together, these trials included 809 infants.
Hodgins' second point interprets a statement we made, quoting the WHO recommendation, 7 and saying that the Cochrane reviews, 1,2 a meta-analysis, 8 and the two trials in The Lancet Global Health 9,10 had not supported an eff ect after hospital births. Our Comment 11 begins with, and is permeated by, an emphasis on newborn mortality. As Hodgins says, community-based trials [8] [9] [10] suggest that the effect on neonatal mortality was similareven when non-significant-when infants were born in hospital. We do not take issue with this. Indeed, we acknowledge the complete statement by Sazawal and colleagues:
10 "The fi ndings in our study suggest that use of chlorhexidine for the reduction of omphalitis is justifi ed, but in an African setting there is insuffi cient evidence to promote this intervention to reduce neonatal mortality."
The emphasis of our Comment was on whether cord application of chlorhexidine might achieve
